Insmed Incorporated
http://www.insmed.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Insmed Incorporated
AN2 Looks To Shift Gears On Phase III Epetraborole Trial On Potentially Lackluster Results
The company said it was pausing enrollment in the Phase III segment of its Phase II/III trial because of efficacy in MAC lung disease.
Evaxion Cancer Vaccines Excite Investors
Shares in the Danish biotech have soared by 110% over plans to prioritize a novel category of AI-identified tumor antigens for its cancer vaccines.
What Do FTC’s Aggressive Moves Against Biopharma Portend For 2024?
The Federal Trade Commission blocked or restricted several deals last year, broadening what it considers to be anticompetitive transactions. Stakeholders are looking to see if the agency will bring similar cases this year and what remedies it will seek to allow deals to go forward.
Scrip Asks...What Does 2024 Hold For Biopharma? Part 2: The Funding Environment, M&A And Partnering
Biotech entrepreneurs tend to be an optimistic group, and there were many pockets of hope for 2024. However, the consensus remains that depressed valuations and paucity of fresh funds will continue to pose a challenge for the sector, and companies will need to prioritize carefully and work even harder to demonstrate and create value.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Pulmonary
- Site Specific
-
Drug Delivery
-
Biotechnology
- Large Molecule
- Liposomes
- Other Names / Subsidiaries
-
- Insmed, Inc.
- Transave Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice